Larry Mahan

Larry Mahan Email and Phone Number

Chief Executive Officer @ OB Pharmaceuticals
Washington, DC, US
Larry Mahan's Location
Washington, District of Columbia, United States, United States
About Larry Mahan

PROFILE: • Successful business professional in innovation management of advanced biomedical technologies with a domestic and international track record in business alliance development. Additional strengths in strategic planning and advanced technologies initiatives development, technology evaluation, entrepreneur guidance, business strategy creation, government relations and policy development.• Accomplished senior scientist in biomedical research encompassing cellular and molecular biology, pharmacology, functional genomics, proteomics, neuroscience, immunology and biochemistry including 12 years at the National Institutes of Health (NIMH, NINDS). Additional strengths in biomedical device engineering, nanotechnology, and IT architectural management. • Entrepreneur and industry consultant in biopharmaceutical facilities and technology platform development in functional genomics and drug discovery. Regional, national and international professional relationships with corporate leadership in the pharmaceutical and biotechnology sectors. In-depth knowledge of the Washington DC region’s bioscience and biodefense industries, academic centers (USM, Hopkins, APL), federal agencies and programs in life sciences (NIH, NIST, BARDA, DARPA, USAMRIID) and other advanced technology R&D centers.• Author and international lecturer on scientific research and biotechnology industry development author of over 100 published articles & abstracts; holder of 4 U.S. patents.Specialties in the biomedical sector: • Drug development in neurological and cardiorenal diseases• Institutional innovation management (IP and contractual R&D implementation) • Needs analyses and solution development including strategic partnership development• Due diligence for grant/equity investment programs for seed and early stage technology opportunities

Larry Mahan's Current Company Details
OB Pharmaceuticals

Ob Pharmaceuticals

View
Chief Executive Officer
Washington, DC, US
Larry Mahan Work Experience Details
  • Ob Pharmaceuticals
    Chief Executive Officer
    Ob Pharmaceuticals
    Washington, Dc, Us
    View
  • Biotechnology Institute
    Chairman
    Biotechnology Institute Jun 2024 - Present
    Washington, District Of Columbia, Us
    Providing leadership and strategic guidance to the Board of the Institute.
    View
  • Ob Pharmaceuticals
    Chief Executive Officer
    Ob Pharmaceuticals Mar 2018 - Present
    London, Ontario, Ca
    OB Pharma is a privately held late preclinical Canadian biopharmaceutical company developing next-gen anti-seizure molecules. We have advanced our most promising lead candidate from our more than 120 NCEs library into final IND-enabling studies. Our molecules demonstrate strong evidence of efficacy for drug refractory epilepsy and seizures resulting from traumatic brain injury. In this capacity: • Lead overall corporate strategy, capital investment efforts and pharma partnering opportunities• Provide strategic guidance on preclinical and clinical development programs• Develop and maintain detailed proforma financials• Manage all intellectual property activities• Served previously on company's Strategic Advisory Board (2016-2018)
    View
  • Madeleine Pharmaceuticals, Inc.
    Chief Scientific Officer
    Madeleine Pharmaceuticals, Inc. Mar 2015 - Present
    Madeleine Pharma has developed a cardiac peptide hormone for the treatment of worsening heart failure in patients with cardiorenal disease. We are currently introducing a recombinant form of the peptide into the U.S. for an IND to conduct a Phase 2 clinical trial based upon findings from previous OUS Phase 2a trials. In this capacity:• Served as Principal Investigator after successfully authoring a Direct-to-Phase II $2m Small Business Innovation Research (SBIR) grant from the National Institute of Heart, Lung and Blood for an IND-enabling GLP toxicology series and scale-up of the recombinant peptide and secured another $3m PII-B grant to enter U.S. Phase 2 a clinical trials.• Managed all CMC aspects of technology transfer, analytics development, process validation and scale-up for the drug substance• Managed all recombinant peptide GLP toxicology studies with successful outcomes (no TRAEs) • Formed the company's internationally recognized Clinical Advisory Board of expert heart failure clinical researchers• Co-developed the FDA clinical and regulatory strategy resulting in successful "green light" outcomes• Co-created the clinical strategy including trial designs, patient demographics, endpoints, site identification and overall trial management structure• Designed alternative peptide drug substance analogues and structure-activity relationship (SAR) strategies
  • Bioconsult Usa
    President/Owner
    Bioconsult Usa Jan 1998 - Jan 2019
    Established a interim private consulting business for the biomedical and healthcare sectors focused on innovation management, technology evaluation, business development and strategic partnerships.In this capacity, provided the following services:• Evaluation and business/IP/regulatory case development for advanced neuromonitoring technologies and neuroregenerative drug development.• Provide assistance to foreign biomedical SMEs on U.S. entry and funding strategies.• Produced center concept, design, and faculty participation plan, as well as co-authored international government funding applications for a $20 million multi-core facility, biopharmaceutical sciences center for the University of Ottawa, ON, Canada. Today this has become the Centre for Biopharmaceutical Sciences and Biotechnology (CRBB) with over 40 faculty members, a graduate program, and the Canadian ICC Research Network and Biofilms in Medicine Initiative.• Created innovative collaborative industry-government research programs for business creation including federal incubator facilities with the National Research Council (NRC/CNRC), Ottawa, ON, Canada leading later to the implementation of the NRC’s Industry Partnership Facilities (IPFs) – start-up technology company collocation program with synergistic NRC research institutes.• Assisted numerous biotech start-ups with corporate strategy development
  • National Heart, Lung, And Blood Institute, Nih
    Director, Office Of Translational Alliances & Coordination (Otac)
    National Heart, Lung, And Blood Institute, Nih Jun 2013 - Feb 2014
    Bethesda, Maryland, Us
    Led OTAC’s mission to accelerate the translation of basic discoveries in cardiovascular, respiratory and blood disorders into innovative diagnostics, devices, therapeutics and mHealth applications through federal funding programs directed at industry and academic institutional translational research efforts. Activities/accomplishments included:• Oversight of the programmatic management of NHLBI’s SBIR/STTR portfolio of ~200 companies representing $80 million in annual investment in seed and early stage biomedical product development.• Implementation of first-in-kind NIH Centers for Accelerated Innovations – a $32 million investment in national consortia of leading academic institutions to advance translational research to commercialization.• Co-development of a multi-program portfolio evaluation system including logic model and more than 100 quantitative metrics.• Increased proactive showcasing of portfolio companies nationally to investors and strategic partners.• Fostering strategic alliances between federal, academic and private sector stakeholders.
    View
  • Children'S National Medical Center
    Director, Innovation And Business Development
    Children'S National Medical Center Aug 2010 - Jan 2013
    Washington, Dc, Us
    Director of Innovation and Business Development for Children’s National Medical Center and its research institutes, the Children’s Research Institute and the newly created $150 million Sheikh Zayed Institute for Pediatric Surgical Innovation. Responsibilities included intellectual property oversight, strategic business alliance development and the advancement of academic entrepreneurship. Areas of focus included therapeutic, diagnostic, device and i/m health application development to advance Children’s National mission is to substantially alter healthcare outcomes for children. Some significant accomplishments include: • the design and implementation of an innovation portfolio management system including adaptation of industry stage gate processes with reporting analytics to an academic research environment for translational/product development oriented research programs.• formalization and management of an enterprise-wide technology transfer infrastructure facilitating a 6-fold increase in IP disclosures.• negotiation and execution of a variety of contractual R&D collaborative agreements to enable faculty-industry strategic partnerships for commercialization.• conception and design of a $10 million Pediatric Innovation Fund for philanthropic seed/early stage investments in promising faculty-driven research programs oriented to pediatric product development (launch planned for 2013).• co-design and implementation of an Innovation and Entrepreneurship Education Program including a core curriculum in Innovation in Healthcare covering the basics of innovation theory (individual, team, enterprise), entrepreneurship best practices, intellectual property, healthcare product development and regulation, market analyses, and business plan basics, as examples.
    View
  • Maryland Biotechnology Center
    Director Of Programs
    Maryland Biotechnology Center Jan 2010 - Aug 2010
    Responsibilities included creation and administration of a $1.85 million grant program for Translational Research, Biotechnology Commercialization projects and Shared Resource Facilities to companies and academic institutions. Additionally provided services in business strategy, capital formation, workforce training and development, federal networking to NIH, NIST and USAMRIID.
  • Maryland Biotechnology Center
    Executive Director
    Maryland Biotechnology Center Nov 2008 - Aug 2010
    As first Executive Director: • Designed and implemented a Governor’s initiative to create the $4 million Maryland Biotechnology Center, a centralized resource for Maryland’s bioscience industry with particular emphasis on entrepreneurial development, translational research and technology commercialization.• Successfully launched first two offices in Q3/2009 including the inaugural website, all marketing materials and a comprehensive entrepreneur resource library with free online access to MedTRACK, Datamonitor, ReCap, Frost & Sullivan, Discovery Logic Synapse, Hoovers and Lexis/Nexis for emergent biocompanies.• As Executive Staff to the Maryland Life Sciences Advisory Board (LSAB), provided all subject content, data acquisition and analysis, and consultant coordination for a 1-1/2 year strategic plan development process.• Organized and conducted more than 25 LSAB Working Group meetings involving >100 subject matter experts from industry, academia and federal labs for recommendation development.• Co-authored BioMaryland 2020, the State Strategic Plan for Life Sciences launched May 2009, a $1.3 billion 10 year plan of investment in bioscience in Maryland.
  • University Of Maryland Biotechnology Institute
    Business Development Liaison, Ord
    University Of Maryland Biotechnology Institute Nov 2005 - Jun 2010
    College Park, Md, Us
    Responsible for accelerating industry partnerships for UMBI technology developments, securing license opportunities, and assisting new enterprise formation from UMBI's research centers. Served on the Patent Review Board performing due diligence oversight on the existing patent portfolio and prospective disclosures.
    View
  • State Of Maryland
    Senior Strategic Advisor, Biosciences
    State Of Maryland Jun 2001 - Nov 2008
    Baltimore, Maryland, Us
    • Implemented DBED’s business development goals and objectives by creating global targeting strategies for the State’s industry cluster development in the biosciences and other advanced technology sectors.• Conducted hundreds of C-suite meetings with biotechnology and pharmaceutical companies spanning the U.S., Europe and Asia on behalf of the State, its bioscience companies and research centers.• Successfully managed business development executives and marketing strategists to achieve cumulative results of more than 125 technology business location/retention decisions representing ~$1.5 billion in capital investment, and >8,000 new and retained jobs from a broad client portfolio including MedImmune, Emergent Biosolutions, Invitrogen, Aeras Global TB Vaccine, Xceleron, Novavax, and KeyGene.• Co-authored and reviewed technology and bioscience legislation for the DBED and the Maryland General Assembly including the Biotechnology Investor Incentive Tax Credit Program that has resulted in ~$50 million in early stage investment in start-up biotechnology companies in MD from 2006-2010.• Performed due diligence on more than 100 biotechnology investment prospects for the Maryland Venture Fund, an 18 year old nationally recognized State grant and equity investment program, contributing to the near 100 technology company portfolio.• Authored/co-authored innovative national project concepts and RFP responses such as the National Pandemic Surge Capacity Facility, the National AgBio Defense Facility, the National Public Health Informatics Center, as well as an Environmental Technology Incubator initiative.
    View
  • Therexcell, Inc.
    Managing Partner/Founder
    Therexcell, Inc. Jan 1998 - Jun 2001
    • Founding partner of an emergent biotechnology company originally focused on unmet therapeutic needs for the treatment of epilepsy, cognitive dysfunction in anesthesia, analgesia, and tinnitus.• Created innovative platform technology concepts for functional genomics and novel high-throughput screening (HTS) assays related to drug candidate development in the treatment of epilepsy. • Successfully negotiated government/private sector collaborative research contracts resulting in cost-saving outsourced solutions for pre-clinical animal models and HTS with the NRC/CNRC, Ottawa.• Generated a comprehensive 5-year operations budget totaling more than $13 million to drive capital formation efforts by the CEO.• Served on the Board of Directors and member of the Scientific Advisory Board.
  • National Institute Of Neurological Disorders And Stroke (Ninds)
    Principal Investigator, Unit Head
    National Institute Of Neurological Disorders And Stroke (Ninds) Jul 1993 - Dec 1997
    Bethesda, Maryland, Us
    Research Unit head and principal investigator in the Laboratory of Neurochemistry, Section on Molecular Neuroscience, responsible for scientific research programs, laboratory training and supervision of post-doctoral fellows, Howard Hughes Medical Institute fellows, NIH summer employment undergraduates, and laboratory technical staff. Previous research experience and academic focus formed a strong interest in the role and regulation of cell-surface receptors and processes involved in intercellular communication. This included: formal training in physiology and pharmacology with a specific emphasis in hormone and neurotransmitter/receptor systems; extensive training in molecular biology with an emphasis in gene expression methodologies, expression vector development, and CNS receptor cloning, mammalian expression systems development and gene expression analyses; and past research experience in biochemistry, membrane biology, and immunology. Adjunct to this focus was the development of (1) functional genomics-based assays aimed at delineating gene expression and phenotypic changes in neurons in response to receptor activation or physiological perturbation, and (2) mammalian expression vectors to deliver desired foreign genes or gene-inactivation constructs to embryonic stem cells and embryonic and adult neurons.
    View
  • National Institute Of Mental Health
    Senior Staff Fellow
    National Institute Of Mental Health Jun 1985 - Jun 1993
    Bethesda, Md, Us
    Supervised and conducted research in mammalian molecular neurobiology leading to the co-discovery of dopamine, adenosine, somatostatin and GABAA receptor subtype genes in the mammalian central nervous system. Additionally designed and utilized self replicating viral- and nonviral-based vectors for transgene expression and antisense molecules to modulate neurotransmitter gene expression in vitro and in vivo.
    View
  • Ucsd
    Doctoral Candidate
    Ucsd 1979 - 1984
    San Diego, Ca, Us
    Doctoral degree in Physiology and Pharmacology, University of California at San Diego, School of Medicine.
    View

Larry Mahan Education Details

  • Uc San Diego
    Uc San Diego
    Physiology & Pharmacology

Frequently Asked Questions about Larry Mahan

What company does Larry Mahan work for?

Larry Mahan works for Ob Pharmaceuticals

What is Larry Mahan's role at the current company?

Larry Mahan's current role is Chief Executive Officer.

What schools did Larry Mahan attend?

Larry Mahan attended Uc San Diego.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.